HRP20110394T1 - Inhibitori interakcije između mdm2 i p53 - Google Patents
Inhibitori interakcije između mdm2 i p53 Download PDFInfo
- Publication number
- HRP20110394T1 HRP20110394T1 HR20110394T HRP20110394T HRP20110394T1 HR P20110394 T1 HRP20110394 T1 HR P20110394T1 HR 20110394 T HR20110394 T HR 20110394T HR P20110394 T HRP20110394 T HR P20110394T HR P20110394 T1 HRP20110394 T1 HR P20110394T1
- Authority
- HR
- Croatia
- Prior art keywords
- 6alkyl
- hydroxy
- hydrogen
- substituted
- heteroaryl
- Prior art date
Links
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000003993 interaction Effects 0.000 title 1
- 101150024228 mdm2 gene Proteins 0.000 title 1
- -1 piperazinylcarbonyl Chemical group 0.000 claims abstract 62
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 47
- 239000001257 hydrogen Substances 0.000 claims abstract 39
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 39
- 125000003118 aryl group Chemical group 0.000 claims abstract 33
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 33
- 125000001424 substituent group Chemical group 0.000 claims abstract 32
- 150000001875 compounds Chemical class 0.000 claims abstract 30
- 125000000217 alkyl group Chemical group 0.000 claims abstract 26
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 25
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims abstract 22
- 150000002431 hydrogen Chemical class 0.000 claims abstract 19
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 14
- 125000004193 piperazinyl group Chemical group 0.000 claims abstract 14
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims abstract 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 11
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims abstract 11
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims abstract 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 6
- 125000003386 piperidinyl group Chemical group 0.000 claims abstract 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract 4
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 claims abstract 4
- 101100439664 Arabidopsis thaliana CHR8 gene Proteins 0.000 claims abstract 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract 2
- 125000001475 halogen functional group Chemical group 0.000 claims 14
- 239000000543 intermediate Substances 0.000 claims 11
- 125000002757 morpholinyl group Chemical group 0.000 claims 9
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 8
- 238000006243 chemical reaction Methods 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 6
- 125000001041 indolyl group Chemical group 0.000 claims 5
- 125000001624 naphthyl group Chemical group 0.000 claims 5
- 125000004076 pyridyl group Chemical group 0.000 claims 5
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 4
- 239000002904 solvent Substances 0.000 claims 4
- 125000003831 tetrazolyl group Chemical group 0.000 claims 4
- 125000005129 aryl carbonyl group Chemical group 0.000 claims 3
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 3
- 125000002541 furyl group Chemical group 0.000 claims 3
- 125000002883 imidazolyl group Chemical group 0.000 claims 3
- 239000012280 lithium aluminium hydride Substances 0.000 claims 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 2
- MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical compound FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 claims 2
- 101100495914 Arabidopsis thaliana ETL1 gene Proteins 0.000 claims 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 2
- 125000000815 N-oxide group Chemical group 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 125000005199 aryl carbonyloxy group Chemical group 0.000 claims 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims 1
- 125000005110 aryl thio group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005204 heteroarylcarbonyloxy group Chemical group 0.000 claims 1
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 1
- 125000005226 heteroaryloxycarbonyl group Chemical group 0.000 claims 1
- 125000005368 heteroarylthio group Chemical group 0.000 claims 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
- 239000012442 inert solvent Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07116889 | 2007-09-21 | ||
| PCT/EP2008/062433 WO2009037308A1 (en) | 2007-09-21 | 2008-09-18 | Inhibitors of the interaction between mdm2 and p53 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110394T1 true HRP20110394T1 (hr) | 2011-06-30 |
Family
ID=38910911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110394T HRP20110394T1 (hr) | 2007-09-21 | 2011-05-25 | Inhibitori interakcije između mdm2 i p53 |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US9573933B2 (ru) |
| EP (1) | EP2203440B1 (ru) |
| JP (1) | JP5438007B2 (ru) |
| CN (2) | CN101868453A (ru) |
| AR (1) | AR068627A1 (ru) |
| AT (1) | ATE502934T1 (ru) |
| AU (1) | AU2008300527B2 (ru) |
| BR (1) | BRPI0817223B8 (ru) |
| CA (1) | CA2699849C (ru) |
| CL (1) | CL2008002798A1 (ru) |
| DE (1) | DE602008005784D1 (ru) |
| DK (1) | DK2203440T3 (ru) |
| ES (1) | ES2363838T3 (ru) |
| HR (1) | HRP20110394T1 (ru) |
| JO (1) | JO2704B1 (ru) |
| MX (1) | MX2010003060A (ru) |
| PA (1) | PA8796901A1 (ru) |
| PE (1) | PE20090817A1 (ru) |
| RU (1) | RU2477724C2 (ru) |
| SI (1) | SI2203440T1 (ru) |
| TW (1) | TWI434841B (ru) |
| UY (1) | UY31349A1 (ru) |
| WO (1) | WO2009037308A1 (ru) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2704B1 (en) | 2007-09-21 | 2013-03-03 | جانسين فارماسوتيكا ان في | Interference inhibition factors between MD2 and B53 |
| US8354444B2 (en) * | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
| AR075235A1 (es) | 2009-02-04 | 2011-03-16 | Janssen Pharmaceutica Nv | Derivados de indol como agentes anticancer. |
| TW201139370A (en) | 2009-12-23 | 2011-11-16 | Lundbeck & Co As H | Processes for the manufacture of a pharmaceutically active agent |
| CN102321034B (zh) * | 2011-06-07 | 2014-08-13 | 中国人民解放军第二军医大学 | 硫代苯二氮卓类化合物及其作为药物的用途 |
| CA2853729A1 (en) | 2011-10-28 | 2013-05-02 | Board Of Regents, The University Of Texas System | Novel compositions and methods for treating cancer |
| ES2410704B1 (es) * | 2011-11-28 | 2014-04-29 | Universitat De Barcelona | Indoleninas fluoradas útiles para el tratamiento del cáncer. |
| AR094116A1 (es) | 2012-12-20 | 2015-07-08 | Merck Sharp & Dohme | Imidazopiridinas sustituidas como inhibidores de hdm2 |
| PL3458101T3 (pl) | 2016-05-20 | 2021-05-31 | F. Hoffmann-La Roche Ag | Koniugaty PROTAC-przeciwciało i sposoby ich stosowania |
| CN110290764B (zh) | 2016-12-21 | 2022-04-29 | 特里弗洛心血管公司 | 心脏瓣膜支撑装置及用于制造和使用该装置的方法 |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001042224A1 (en) | 1999-12-09 | 2001-06-14 | Mitsubishi Pharma Corporation | Carboxyamido derivatives |
| ES2566056T3 (es) * | 2001-03-29 | 2016-04-08 | Eli Lilly And Company | N-(2-ariletil)bencilaminas como antagonistas del receptor 5-HT6 |
| WO2003040402A2 (en) * | 2001-11-09 | 2003-05-15 | The Regents Of The University Of California | Alpha-helix mimicry by a class of organic molecules |
| SE0400284D0 (sv) | 2004-02-10 | 2004-02-10 | Astrazeneca Ab | Novel compounds |
| US7540139B2 (en) * | 2004-08-16 | 2009-06-02 | Rowse Hydraulic Rakes Co., Inc. | Foldable hay rake |
| EP1809622B1 (en) * | 2004-09-22 | 2010-07-21 | Janssen Pharmaceutica N.V. | Inhibitors of the interaction between mdm2 and p53 |
| EP1865963A2 (en) * | 2005-02-18 | 2007-12-19 | Acadia Pharmaceuticals Inc. | Triazadibenzoazulene compounds useful for the treatment and prevention of pain and screening methods therefor |
| US7576082B2 (en) * | 2005-06-24 | 2009-08-18 | Hoffman-La Roche Inc. | Oxindole derivatives |
| EP2001868B1 (en) | 2006-03-22 | 2013-07-17 | Janssen Pharmaceutica N.V. | Inhibitors of the interaction between mdm2 and p53 |
| TW200922557A (en) * | 2007-08-06 | 2009-06-01 | Janssen Pharmaceutica Nv | Substituted phenylenediamines as inhibitors of the interaction between MDM2 and p53 |
| JO2704B1 (en) | 2007-09-21 | 2013-03-03 | جانسين فارماسوتيكا ان في | Interference inhibition factors between MD2 and B53 |
-
2008
- 2008-09-11 JO JO2008406A patent/JO2704B1/en active
- 2008-09-17 CL CL2008002798A patent/CL2008002798A1/es unknown
- 2008-09-18 DK DK08804373.2T patent/DK2203440T3/da active
- 2008-09-18 DE DE602008005784T patent/DE602008005784D1/de active Active
- 2008-09-18 AT AT08804373T patent/ATE502934T1/de not_active IP Right Cessation
- 2008-09-18 US US12/678,961 patent/US9573933B2/en active Active
- 2008-09-18 SI SI200830267T patent/SI2203440T1/sl unknown
- 2008-09-18 JP JP2010525346A patent/JP5438007B2/ja not_active Expired - Fee Related
- 2008-09-18 WO PCT/EP2008/062433 patent/WO2009037308A1/en active Application Filing
- 2008-09-18 EP EP08804373A patent/EP2203440B1/en active Active
- 2008-09-18 MX MX2010003060A patent/MX2010003060A/es active IP Right Grant
- 2008-09-18 CN CN200880117463A patent/CN101868453A/zh active Pending
- 2008-09-18 RU RU2010115765/04A patent/RU2477724C2/ru active
- 2008-09-18 CA CA2699849A patent/CA2699849C/en active Active
- 2008-09-18 ES ES08804373T patent/ES2363838T3/es active Active
- 2008-09-18 BR BRPI0817223A patent/BRPI0817223B8/pt not_active IP Right Cessation
- 2008-09-18 AU AU2008300527A patent/AU2008300527B2/en not_active Ceased
- 2008-09-18 CN CN201510083830.XA patent/CN104761541A/zh active Pending
- 2008-09-19 TW TW097135916A patent/TWI434841B/zh active
- 2008-09-19 PA PA20088796901A patent/PA8796901A1/es unknown
- 2008-09-19 UY UY31349A patent/UY31349A1/es unknown
- 2008-09-19 PE PE2008001643A patent/PE20090817A1/es not_active Application Discontinuation
- 2008-09-19 AR ARP080104085A patent/AR068627A1/es unknown
-
2011
- 2011-05-25 HR HR20110394T patent/HRP20110394T1/hr unknown
-
2017
- 2017-01-04 US US15/398,291 patent/US20170112818A1/en not_active Abandoned
-
2018
- 2018-05-17 US US15/982,043 patent/US20180263966A1/en not_active Abandoned
-
2019
- 2019-12-18 US US16/718,955 patent/US11583524B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110394T1 (hr) | Inhibitori interakcije između mdm2 i p53 | |
| AU2018353150B2 (en) | Methods of using EHMT2 inhibitors in treating or preventing blood disorders | |
| CA2579915A1 (en) | Indole derivatives and their use as inhibitors of p53-mdm2 interaction | |
| ES2666870T3 (es) | Derivado de dispiropirrolidina | |
| TWI808067B (zh) | 作為ehmt2抑制劑之胺取代的雜環化合物及其使用方法 | |
| KR102292293B1 (ko) | 항감염성 화합물 | |
| RU2701156C2 (ru) | Азотсодержащие гетероциклические производные и их применение в фармацевтических препаратах | |
| HRP20160374T1 (hr) | Farmaceutski spojevi | |
| HRP20191655T1 (hr) | N-(5s,6s,9r)-5-amino-6-(2,3-difluorofenil)-6,7,8,9-tetrahidro-5h-ciklohepta[b]piridin-9-il-4-(2-okso-2,3-dihidro-1h-imidazo[4,5-b]piridin-1-il)piperidin-1-karboksilat sol | |
| JP2014524441A (ja) | 抗腫瘍剤としての三環式化合物 | |
| JP2022550436A (ja) | 抗ウイルス性複素環化合物 | |
| TW201625536A (zh) | 抑制組蛋白去甲基酶之化合物及方法 | |
| AR040963A1 (es) | Compuestos que inhiben la adhesion celular mediada por integrina alfa 4, un procedimiento de preparacion y composicion farmaceutica que los contiene | |
| AR068846A1 (es) | Compuestos derivados de pirrolo (2,3d)-pirimidina inhibidores de la actividad de pkb, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos como agentes anticancer | |
| RU2008125813A (ru) | Производные индол-3-ил-карбонил-спиро-пиперидина | |
| AR091176A1 (es) | Pirrodilina-2-carboxamidas sustituidas | |
| HRP20150139T1 (hr) | Tetrahidrofenanthridinoni i tetrahidrociklopentakinolinoni kao inhibitori parp i polimerizacije tubulina | |
| HRP20220512T1 (hr) | Supstituirani pirazolopirimidini kao aktivatori glukocerebrozidaze | |
| AR054890A1 (es) | Derivados de quinolina como agentes antibacterianos | |
| WO2015153498A1 (en) | Inhibitors of histone demethylases | |
| HRP20160011T1 (hr) | Imidazopiridazini kao inhibitori akt kinaze | |
| CN111727189B (zh) | 基于吡啶酮的表观遗传修饰剂及其用途 | |
| AR084152A1 (es) | Compuestos de triazolopirimidina como inhibidores de pde10a, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades del snc | |
| ES2626801T3 (es) | Compuestos de triazolopiridina como inhibidores de pde10a | |
| AR087211A1 (es) | ANTAGONISTAS DE CRTh2 |